Lonza Breaks Ground on Singapore Biologics Plant

Lonza and Bio*One Capital (Singapore) have broken ground on a previously announced project to build a large-scale commercial mammalian cell culture manufacturing facility in Singapore (CW, Dec. 13, 2006, p. 29). The plant is being built in the Tuas Biomedical Park, and will be Lonza’s second large-scale mammalian manufacturing plant in Singapore and its third worldwide. It will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 liters-20,000 liters. Completion is scheduled by 2011. The investment could total $350 million...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers